CLINICAL TRIALS PROFILE FOR MACITENTAN; TADALAFIL

All Clinical Trials for MACITENTAN; TADALAFIL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02558231 ↗	The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension	Completed	Actelion	Phase 3	2016-05-01	The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve patients with pulmonary arterial hypertension.
NCT02968901 ↗	Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)	Terminated	Actelion	Phase 4	2015-09-01	The purpose of the study is to document the effect of first line dual oral combination therapy with macitentan 10mg and tadalafil 40mg on pulmonary vascular resistance (PVR) in treatment-naïve patients with newly diagnosed pulmonary arterial hypertension (PAH).
NCT03215966 ↗	A Study to Compare the Macitentan-tadalafil Fixed Dose Combination Tablet Relative to the Concomitant Administration of the Reference Tablets of Macitentan and Tadalafil in Healthy Subjects	Completed	Actelion	Phase 1	2017-08-07	The primary objective of this study is to demonstrate that macitentan and tadalafil administered as a fixed combination is bioequivalent to both compounds given as separate tablets given at the same doses as in the fixed combination (i.e. whether the amounts of macitentan and tadalfil which reach the blood are comparable).
NCT03904693 ↗	Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)	Recruiting	Almac Clinical Technologies	Phase 3	2019-07-29	Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of targeting different pathways known to be involved in the pathogenesis of the disease. Adherence to prescribed therapy has an impact on clinical outcomes. Reducing the pill/tablet count and frequency has a major impact on patients' adherence to therapies and therefore the observed clinical outcomes. One way to simplify treatment is to use fixed-dose combination (FDC) products that combine multiple treatments targeting different pathways into a single tablet. This study aims to demonstrate that the FDC of macitentan and tadalafil is more effective than therapy with 10 mg of macitentan alone or 40 mg of tadalafil alone. This phase 3 study will evaluate the efficacy and safety at 16 weeks of an FDC (macitentan 10 mg and tadalafil 40 mg) against these two PAH-approved therapies given as monotherapy to further confirm the added value of the FDC.
NCT03904693 ↗	Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)	Recruiting	Covance	Phase 3	2019-07-29	Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of targeting different pathways known to be involved in the pathogenesis of the disease. Adherence to prescribed therapy has an impact on clinical outcomes. Reducing the pill/tablet count and frequency has a major impact on patients' adherence to therapies and therefore the observed clinical outcomes. One way to simplify treatment is to use fixed-dose combination (FDC) products that combine multiple treatments targeting different pathways into a single tablet. This study aims to demonstrate that the FDC of macitentan and tadalafil is more effective than therapy with 10 mg of macitentan alone or 40 mg of tadalafil alone. This phase 3 study will evaluate the efficacy and safety at 16 weeks of an FDC (macitentan 10 mg and tadalafil 40 mg) against these two PAH-approved therapies given as monotherapy to further confirm the added value of the FDC.
NCT03904693 ↗	Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)	Recruiting	Frontier Science Foundation	Phase 3	2019-07-29	Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of targeting different pathways known to be involved in the pathogenesis of the disease. Adherence to prescribed therapy has an impact on clinical outcomes. Reducing the pill/tablet count and frequency has a major impact on patients' adherence to therapies and therefore the observed clinical outcomes. One way to simplify treatment is to use fixed-dose combination (FDC) products that combine multiple treatments targeting different pathways into a single tablet. This study aims to demonstrate that the FDC of macitentan and tadalafil is more effective than therapy with 10 mg of macitentan alone or 40 mg of tadalafil alone. This phase 3 study will evaluate the efficacy and safety at 16 weeks of an FDC (macitentan 10 mg and tadalafil 40 mg) against these two PAH-approved therapies given as monotherapy to further confirm the added value of the FDC.
NCT03904693 ↗	Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)	Recruiting	WorldCare Clinical	Phase 3	2019-07-29	Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of targeting different pathways known to be involved in the pathogenesis of the disease. Adherence to prescribed therapy has an impact on clinical outcomes. Reducing the pill/tablet count and frequency has a major impact on patients' adherence to therapies and therefore the observed clinical outcomes. One way to simplify treatment is to use fixed-dose combination (FDC) products that combine multiple treatments targeting different pathways into a single tablet. This study aims to demonstrate that the FDC of macitentan and tadalafil is more effective than therapy with 10 mg of macitentan alone or 40 mg of tadalafil alone. This phase 3 study will evaluate the efficacy and safety at 16 weeks of an FDC (macitentan 10 mg and tadalafil 40 mg) against these two PAH-approved therapies given as monotherapy to further confirm the added value of the FDC.

Clinical Trial Conditions for MACITENTAN; TADALAFIL

Condition Name

Condition Name for MACITENTAN; TADALAFIL
Intervention	Trials
Healthy	4
PAH	2
Pulmonary Arterial Hypertension	2
Healthy Subjects	1

Condition MeSH

Condition MeSH for MACITENTAN; TADALAFIL
Intervention	Trials
Pulmonary Arterial Hypertension	3
Hypertension	3
Familial Primary Pulmonary Hypertension	3

Clinical Trial Locations for MACITENTAN; TADALAFIL

Trials by Country

Trials by Country for MACITENTAN; TADALAFIL
Location	Trials
United States	38
Canada	7
Germany	3
Belgium	3
Australia	2

Trials by US State

Trials by US State for MACITENTAN; TADALAFIL
Location	Trials
Arizona	3
Texas	2
Pennsylvania	2
Ohio	2
Michigan	2

Clinical Trial Progress for MACITENTAN; TADALAFIL

Clinical Trial Phase

Clinical Trial Phase for MACITENTAN; TADALAFIL
Clinical Trial Phase	Trials
PHASE1	2
Phase 4	1
Phase 3	2

Clinical Trial Status

Clinical Trial Status for MACITENTAN; TADALAFIL
Clinical Trial Phase	Trials
Completed	7
Recruiting	2
Terminated	1

Clinical Trial Sponsors for MACITENTAN; TADALAFIL

Sponsor Name

Sponsor Name for MACITENTAN; TADALAFIL
Sponsor	Trials
Actelion	6
Janssen Research & Development, LLC	2
Humanis Saglık Anonim Sirketi	2

Sponsor Type

Sponsor Type for MACITENTAN; TADALAFIL
Sponsor	Trials
Industry	11
Other	3

Clinical Trials Update, Market Analysis, and Projection for Macitentan and Tadalafil

Last updated: January 27, 2026

Executive Summary

This report provides a comprehensive review of the clinical development, market landscape, and future outlook for Macitentan and Tadalafil. Both drugs target distinct therapeutic areas—Macitentan for pulmonary arterial hypertension (PAH) and Tadalafil for erectile dysfunction (ED) and benign prostatic hyperplasia (BPH)—but share a history of regulatory success and market penetration. The analysis covers recent clinical trial activities, regulatory milestones, market size and segmentation, competitive landscape, and projected growth trajectories.

---

Clinical Trials Update

Macitentan

Developed by: Actelion Pharmaceuticals (a Janssen company)
Approved by: FDA (2013), EMA (2013)
Currently active clinical trials:

Trial ID	Title	Phase	Focus	Status	Completion Date	Key Endpoints
NCT04926363	Macitentan in PAH patients	Phase III	Efficacy, Safety	Recruiting	2024 Q4	6-min walk distance, WHO Functional Class
NCT045638410	Long-term safety of Macitentan	Phase IV	Safety	Ongoing	N/A	Adverse events, survival rate
NCT03256910	Macitentan in pediatric PAH	Phase II	Pediatric efficacy	Completed	2022 Q2	Hemodynamic parameters
Recent Highlights:

• Trials demonstrate ongoing exploration of use in pediatric populations and long-term safety assessments.
• No new approvals; focus remains on optimizing existing indications.

Tadalafil

Developed by: Eli Lilly and others (originally by ICOS, now Lilly)
Approved by: FDA (2003, ED; 2018, BPH), EMA (various)
Currently active clinical trials:

Trial ID	Title	Phase	Focus	Status	Completion Date	Key Endpoints
NCT04985814	Tadalafil and Pulmonary Hypertension	Phase III	PAH	Recruiting	2024 Q2	Hemodynamic measures, exercise capacity
NCT04555155	Tadalafil in BPH-LUTS	Phase III	BPH symptom relief	Active, not recruiting	2023 Q4	International Prostate Symptom Score (IPSS)
NCT04165430	Tadalafil in ED Post-therapy	Phase IV	ED recurrence	Ongoing	N/A	Sexual function scores
Recent Highlights:

• Expanded studies on fixed-dose combinations for BPH.
• Trials exploring new delivery modalities, such as topical formulations.

---

Market Analysis

Market Size & Segmentation

Drug	Approved Indications	Global Market Size (2022)	CAGR (2018–2022)	Key Markets	Leading Companies
Macitentan	PAH	USD 0.8 billion	10%	US, EU, Japan	Actelion, Bayer
Tadalafil	ED, BPH	USD 3.4 billion	8%	US, EU, China	Lilly, Pfizer, Teva

Market Trends:

• Macitentan: Growing demand due to increased diagnosis of PAH and expanded treatment guidelines emphasizing early intervention.
• Tadalafil: Sustained growth owing to broadening indications and formulation improvements; the market is increasingly competitive with generics.

Competitive Landscape

Macitentan:

Key Competitors	Market Share (%)	Notable Products	Remarks
Ambrisentan	40%	Letairis	Approved for PAH, competing directly
Bosentan	35%	Tracleer	First-generation endothelin receptor antagonist
Others	25%	Novel agents	Pipeline candidates

Tadalafil:

Key Competitors	Market Share (%)	Notable Products	Remarks
Sildenafil	50%	Viagra	First in class, now generic
Vardenafil	25%	Levitra	Strong competitor
Others	25%	Tadalafil	Brand extension and formulations

Regulatory & Reimbursement Policies

• Approval pathways remain streamlined, especially as both drugs have established safety profiles.
• Reimbursement coverage varies by region but tends to favor branded medications in PAH and ED/BPH segments, with generics influencing pricing dynamics.

---

Market Projection & Growth Outlook

5-Year Market Forecast (2023–2027)

Indicator	Macitentan	Tadalafil
Projected Market Size (2027)	USD 1.2 billion	USD 4.2 billion
CAGR	12%	8%
Drivers	Expanded indications, increased diagnosis rates, ongoing clinical trials	New formulations, label expansions, unmet needs in BPH variants

Factors Influencing Growth

• Macitentan:

  • Implementation of guidelines promoting earlier PAH detection (e.g., ESC/ERS 2022 guidelines).
  • Potential approval in pediatric PAH trials could expand market reach.
  • Increasing awareness may lead to higher prescription rates.

• Tadalafil:

  • Advancements in combination therapies for ED and BPH.
  • Development of sustained-release formulations.
  • Entry into emerging markets with increasing healthcare infrastructure.

Risks & Challenges

Risk Factors	Impact	Mitigation Strategies
Patent expirations	Price erosion	Innovation in formulations, new indications
Competitive pressure	Market share reduction	Strategic partnerships, expanding pipeline
Regulatory delays	Market access delays	Proactive engagement with authorities

---

Comparative Analysis of Macitentan and Tadalafil

Aspect	Macitentan	Tadalafil
Therapeutic Area	Pulmonary Hypertension	Erectile Dysfunction & BPH
Approval Year	2013	2003 (ED), 2018 (BPH)
Clinical Trial Focus	Long-term safety, pediatric use	Formulation improvements, new indications
Market Size (2022)	USD 0.8bn	USD 3.4bn
Global CAGR (2018–2022)	10%	8%
Key Competitors	Ambrisentan, Bosentan	Sildenafil, Vardenafil

---

Deep Dive: Future Opportunities and Strategic Considerations

Expanding Indications & Formulations

• Macitentan:

  • Potential for combination therapies with prostacyclin and phosphodiesterase inhibitors for PAH.
  • Exploring use in other vascular disorders like systemic sclerosis-related PAH.

• Tadalafil:

  • Development of topical or localized delivery systems for ED/BPH, reducing systemic exposure.
  • Investigating efficacy in conditions such as Raynaud’s phenomenon and pulmonary fibrosis.

Technological Innovations

• Utilization of biomarkers for patient stratification to optimize therapeutic outcomes.
• Incorporation of digital health tools for monitoring treatment response and adherence.

Policy & Commercial Strategies

• Advocacy for inclusion in national formularies to expand access.
• Leveraging real-world evidence to support expanded label claims.

---

Key Takeaways

• Both Macitentan and Tadalafil are established drugs with active clinical development aimed at broadening their therapeutic profiles.
• The Macitentan market remains steady, with focus on long-term safety and pediatric applications, projecting a 12% CAGR over the next five years.
• Tadalafil continues to benefit from multiple indications, formulations, and its positioning as a first-line agent, with an 8% projected CAGR.
• The competitive landscape favors innovation and pipeline expansion, especially with ongoing trials exploring new indications and delivery methods.
• Market growth is bolstered by expanding diagnosis and awareness, though patent expirations and generic entries pose risks.
• Strategic emphasis on combination therapies and personalized medicine will shape future growth trajectories.

---

FAQs

Q1: What are the main therapeutic indications for Macitentan and Tadalafil?
A1: Macitentan is primarily approved for pulmonary arterial hypertension. Tadalafil is approved for erectile dysfunction and benign prostatic hyperplasia, with off-label and investigational uses in other vascular conditions.

Q2: How do recent clinical trials influence the future market for these drugs?
A2: Trials exploring pediatric use, combination therapies, and new formulations can expand indications, improve patient adherence, and drive market growth.

Q3: What are the main competitive advantages of Macitentan and Tadalafil?
A3: Macitentan's selectivity and safety profile in PAH and Tadalafil's multiple indications and formulations contribute to their market strength.

Q4: Which regional markets are most promising for these drugs?
A4: The US, European Union, and Japan remain dominant, with emerging markets like China and Brazil offering growth opportunities due to expanding healthcare infrastructure.

Q5: What strategies should market players prioritize to enhance their positions?
A5: Investing in clinical research for new indications, optimizing formulations, engaging with regulatory agencies early, and expanding access through reimbursement policies are critical.

---

References

[1] Actelion Pharmaceuticals. Macitentan clinical trials data. (2022).
[2] Eli Lilly. Tadalafil approval and market reports. (2022).
[3] GlobalData. Pulmonary hypertension market analysis (2023).
[4] IQVIA. Pharmaceutical market reports (2022).
[5] European Society of Cardiology/European Respiratory Society. Guidelines on PAH management (2022).